Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate ...

Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where Sanofi (NASDAQ:SNY) stands against other best immunology stocks to buy now.

Berenberg analyst Luisa Hector raised the firm’s price target on Sanofi (SNY) to EUR 120 from EUR 115 and keeps a Buy rating on the ...

Banks are gearing up to offload the €8.65 billion ($9.5 billion) debt package backing Clayton Dubilier & Rice’s purchase of a ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the ...

As such, Sanofi is still relatively cheap at its current market capitalization of $131 ... long position in the shares of SNY either through stock ownership, options, or other derivatives.

The stock has a market capitalization of $149.53 billion ... of $53.85 and a two-hundred day moving average of $52.83. Sanofi has a 12 month low of $45.22 and a 12 month high of $60.12.

Sanofi India share price gains were likely driven by its quarterly results performance and the dividend announcements, even though stock gave away most gains as the stock market crashed and Sensex ...

In this article, we are going to take a look at where Sanofi (NASDAQ ... stocks present lucrative investment opportunities. The market for immunotherapy medications is expected to rise at a ...